Article ID Journal Published Year Pages File Type
8630337 Diabetes Research and Clinical Practice 2017 21 Pages PDF
Abstract
In patients treated with regular U-500 insulin, adjuvant exenatide ER therapy showed no significant improvement in HbA1C, but did show modest weight loss as well as decreased insulin requirements to achieve a HbA1C that was comparable to baseline.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology
Preview
The impact of extended release exenatide as adjuvant therapy on hemoglobin A1C, weight, and total daily dose of insulin in patients with type 2 diabetes mellitus using U-500 insulin
Authors
, , , ,